Translations:SGLT2 inhibitor/43/en

External links

• "FDA revises label of diabetes drug canagliflozin". U.S. Food and Drug Administration. 15 January 2016.
• "FDA Drug Safety Communication: FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR)". U.S. Food and Drug Administration. 18 May 2016.
• "FDA Drug Safety Communication: Interim clinical trial results find increased risk of leg and foot amputations, mostly affecting the toes, with the diabetes medicine canagliflozin (Invokana, Invokamet); FDA to investigate". U.S. Food and Drug Administration. 9 May 2017.
• "Warning use metformin in certain patients with reduced kidney function". U.S. Food and Drug Administration. 14 November 2017.
• "Warning: infection of genital area with SGLT2 inhibitors for diabetes". U.S. Food and Drug Administration. 7 September 2018.